SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is generating significant buzz as a unique permissionless brand, driven by a dedicated community actively launching diverse real-world products, including Kendu Spice and Kendu Energy. Community members are showcasing strong conviction and consistent IRL efforts, positioning KENDU as a compelling long-term hold in the crypto market.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is trending as the community eagerly discusses its strategic integration with World Liberty Finance for USD1 payroll and card services. Holders are also highlighting its ISO 20022 and MiCA compliance, along with anticipated launches like the Super App and expanding partnerships with platforms such as Stellar and Ripple. This collective optimism stems from a strong belief in ZBCN's undervalued status and its growing real-world utility in the crypto payment sector.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce Holding PLC (ADR) is generating significant buzz, with the community celebrating its consistent upward momentum and frequent "all-time highs," often after temporary price anomalies. Key drivers of conversation include strong anticipation for new contracts in its defense sectorespecially for MTU engines in military vehicles and the MV-75 programalongside optimism for its Small Modular Reactor (SMR) division to secure deals for energy infrastructure and data centers. Further fueling positive sentiment are ongoing share buyback programs and high expectations for the company's robust full-year earnings report expected in February.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is generating significant conversation due to its foundational role in programmable money and multi-chain interoperability, with the community actively discussing its Overledger technology powering live initiatives like the UK's tokenized deposits pilot with major financial institutions. Despite some past price volatility, holders remain confident in QNT's limited supply and strategic positioning to bridge legacy finance with future CBDC systems. Many view current levels as an accumulation opportunity, anticipating substantial growth driven by its enterprise utility and recent infrastructure developments.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is a major talking point after Madryn Asset Management disclosed a 91% stake, leading to widespread community speculation about an impending short squeeze. The exceptionally low public float, combined with discussions around potential privatization or delisting, is fueling strong bullish sentiment for substantial price appreciation. Investors are actively discussing this unique ownership structure as the primary catalyst for the stock's notable upward momentum.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma ($FIG) is trending amid significant downward pressure, with community chatter centered on its post-IPO performance, substantial insider selling, and upcoming lock-up expirations, fueling concerns about its valuation. While some view the rapid decline as a "scam IPO" or vulnerability to AI replacing design roles, others see an oversold opportunity, highlighting Figma's strong product adoption, market share dominance, and strategic AI integrations as potential drivers for a rebound.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending amid community discussions surrounding the delayed Digital Asset Market Clarity Act, with concerns about banks influencing stablecoin regulation. Despite regulatory uncertainty, the community highlights strong network fundamentals, growing institutional demand, and high staking activity, largely anticipating significant upward price action and upcoming upgrades.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

The Internet Computer (ICP) is trending due to active discussions surrounding its "Mission 70" tokenomics, aimed at significantly reducing inflation and boosting network usage. The community is highlighting ICP's advanced technology, including Chain Fusion and AI integration, positioning it as an undervalued asset with real-world utility for decentralized cloud services. Many foresee a major move driven by fundamental adoption, despite ongoing debates about its past price volatility.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASP Isotopes Inc

ASP Isotopes is trending after confirming all regulatory approvals for its Renergen acquisition, integrating helium and LNG production into its business. This move, alongside its core isotope technologies for critical sectors like semiconductors, biopharma, and nuclear energy, fuels community debate regarding management's execution track record versus the company's long-term potential in high-demand markets. While some voice frustration over past delays in commercial product shipments, others see a strategically diversified play poised to capitalize on the growing demand for critical materials driven by advancements in AI and nuclear power.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending following a significant share buyback announcement and the launch of a new high-protein menu, alongside reaching its 4,000th restaurant milestone. Community discussions heavily feature skepticism about the stock's ability to sustain gains, as concerns over perceived reduced portion sizes, value, and intense competition continue to drive conversation.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW YORK – December 9, 2025 – Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://psyencebiomed.com/ceo-year-end-letter-to-shareholders">today released a year-end Letter</a> from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026.In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science.“We recruited and dosed our first patients in a Phase IIb study. Through a further investment in <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://psylabs.life/">PsyLabs</a> we secured our psychedelic compound supply chain and became the only listed company with an investment in sustainable Ibogaine at source in Africa. We commenced studies in the exciting field of Longevity and ended the year debt free with over USD $9 million in cash reserves.”<h3>Clinical Progress and Phase IIb Trial Momentum</h3>Psyence BioMed advanced its Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder in palliative care. Multiple patients were dosed across several Australian clinical sites, supported by a partnership with Southern Star Research, one of Australia’s leading clinical research organisations.<h3>Advancing Nature-Derived Manufacturing and Supply Chain Leadership</h3>The Company strengthened its vertical integration through a multi-million-dollar follow-on investment in PsyLabs, securing GMP compliant nature-derived psilocybin and ibogaine supply for current and future programs. Psyence BioMed also announced a breakthrough in high purity ibogaine production, reinforcing its manufacturing advantage.<h3>Regulatory Tailwinds in Australia</h3>Aufrichtig noted the importance of the Australian Therapeutic Goods Administration’s (TGA) public consultation on psilocybin-assisted therapy for existential distress in patients with life-limiting illness – a development closely aligned with the Company’s clinical trial. If approved, the amendment would enable supervised access through the Authorised Prescriber framework and expand the eligible prescriber group to include palliative-care specialists.<img style="height:auto;" src="https://psyencebiomed.com/wp-content/uploads/2024/02/2.jpg" alt="" srcset="https://psyencebiomed.com/wp-content/uploads/2024/02/2-200x70.jpg 200w, https://psyencebiomed.com/wp-content/uploads/2024/02/2-400x140.jpg 400w, https://psyencebiomed.com/wp-content/uploads/2024/02/2-600x210.jpg 600w, https://psyencebiomed.com/wp-content/uploads/2024/02/2-800x280.jpg 800w, https://psyencebiomed.com/wp-content/uploads/2024/02/2-1200x420.jpg 1200w, https://psyencebiomed.com/wp-content/uploads/2024/02/2.jpg 2000w" sizes="100vw" width="2000" height="700"><h3>A Unique Position in Longevity Science</h3>“Psyence BioMed is currently the only publicly listed psychedelics company investing meaningfully in longevity science,” said Aufrichtig. “Our focus is on the emotional, neurobiological, and existential dimensions of aging, and we believe psychedelic-assisted therapy will play a central role in improving healthspan – not just lifespan.”<h3>2026 Outlook</h3>The Company plans to accelerate enrollment in its Phase IIb clinical trial, expand its manufacturing footprint, pursue additional longevity-focused indications, and evaluate strategic partnership opportunities throughout 2026.The full CEO Letter is available <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://psyencebiomed.com/ceo-year-end-letter-to-shareholders/">here</a>.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://psyencebiomed.com/ceo-year-end-letter-to-shareholders/">CEO Letter 2025</a><h3>Forward Looking Statements</h3>This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial, the expansion of the Company’s current and future programs, and the expansion of the Company’s manufacturing capabilities. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule, the Company will secure the necessary regulatory and other consents required to expand its current and future programs, and that the demand for psychedelic-assisted therapy will continue to increase. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-289285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Psyence BioMed summarized its successful 2025 clinical and supply-chain efforts, positioning for trial expansion and longevity research in 2026.

Others

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence BioMed as the first – and currently the only – publicly listed company to investigate psilocybin’s potential impact on biological markers associated with aging and longevity. A successful trial could redefine human longevity and transform the future of aging.Longevity science is gaining unprecedented global attention, driven by rapidly aging populations, escalating healthcare costs, and the visibility of figures like Bryan Johnson, who has openly explored both psychedelic therapies and longevity optimization. Simultaneously, scientific literature continues to build support for the intersection of psychedelics and aging biology. Recent preclinical research has shown that psilocin, psilocybin’s active metabolite, extended survival in aged mouse models and increased the lifespan of human skin and lung cells by more than 50 per cent (<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=fYmoqTfCjBZWcGz8V1JskJhFG_uolRewQpV-bi1RaRsEryoNNMdonMrkWB3SqGWvWg0qhdj3GJWOxsqlXNgRrWQRcRs80DacDb0ArFTFfka8huTHNHeaTVQh9rj0eXMdFTqGcWkE8MdxnKz_E6UtlKazGIOIDwfqrsSKCx7HeD4=">Source</a>). Additional studies suggest psilocybin may modulate cellular aging by reducing oxidative stress, preserving telomere length, enhancing neuroplasticity, and activating key longevity-associated pathways (<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=fYmoqTfCjBZWcGz8V1JskCgz7HXxcl1tb1YSCpMByydkseHXd1kejdDKddRuuLPDK-IWX9sv3MK1GJmyxO84GKjb_CK-05Vpo8Y1eUrWdQHH34IQ1RIem6VnMUkvdHA7XWkMDIaiyS_6wlTKwqI0kviZ_gcQBhSFJPjwmxYN0p6OvPeP6VR4aydoQxv_-JFC">Source</a>).Working closely with an academic neuroscience faculty, Psyence BioMed is developing an accelerated preclinical protocol designed to evaluate whether psilocybin influences biological mechanisms tied to aging. The study will examine biomarkers related to cellular stress, inflammation, mitochondrial function, and behavioural indicators associated with healthspan and lifespan. The Company has commenced the project, with full acceleration anticipated early in the new year following ethics approval.The research will be conducted under the leadership of Dr. Tanya Calvey, PhD, an internationally recognized neuroscientist specializing in translational neuropsychopharmacology. Dr. Calvey’s work bridges human neuroimaging, molecular biology, and neurohistology to explore how psychoactive compounds influence long-term brain health and cellular resilience.“The scientific community is only beginning to uncover the potential links between psychedelics and longevity,” said Dr. Tanya Calvey. “Psilocybin modulates inflammation, neural connectivity, and cellular stress responses – all central to how we understand aging biology. The collaboration with Psyence BioMed enables us to rigorously investigate these mechanisms and generate evidence that could guide future human studies.”Psyence BioMed Chief Executive Officer, Jody Aufrichtig, reinforced the significance of this initiative, particularly within the broader longevity movement.“Longevity is quickly emerging as one of the most important global health frontiers,” said Aufrichtig. “With public influencers like Bryan Johnson elevating longevity science and exploring psychedelic-assisted interventions, there is tremendous interest in understanding how psilocybin may influence biological aging. As the first publicly listed company actively pursuing this research, Psyence BioMed is positioned at the forefront of an entirely new therapeutic arena.This longevity initiative complements Psyence BioMed’s ongoing clinical development programs, including its psilocybin-assisted therapy trial for existential distress in palliative care patients in Australia. Together, these programs advance the Company’s mission to explore the full therapeutic potential of psilocybin and ibogaine across multiple dimensions of human health – from mental wellness to long-term biological wellbeing.About Psyence BioMedPsyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.Contact Information for Psyence Biomedical Ltd. Email: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=XQW2Y0Fa0-FxEjV63NYOwvGdk0cTKvWhozbeHJ0vxO29rFCcfLQstxrPLpBUpNfpzmrd4WxiYpyVt93o5_rum3uQX_s0CpKfLRE-YqYueIU=">ir@psyencebiomed.com</a>&nbsp;&nbsp;&nbsp; Media Inquiries: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=IvKu5Pl-QkcNUcqTqZZulR2XWJNXenfNrThxr5pm_tykE-HvoIlt0QeDeOKiAW0TWyqdn-FnWuBNI9lobyAx6BJP3LgcG7giwPEsRKZ1LgNnPPOWbRVT7BEn6rOJZIaP">media@psyencebiomed.com</a> General Information: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=q_k_pr10fWV3vFgPus8ajT5amCUP9DDYOL32eHu-y8PRIL8081Gb-xBMAOIFsRUJc6PMAK3guPgg2we_vz6cMQCMdbtGTyEVec13-UqEPkk=">info@psyencebiomed.com</a>Investor Contact: Michael Kydd Investor Relations Advisor <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=89WwssPQnVkGaFixvMLmnD8hcHVGC-sEEJew4-H1pRmWVfOMn6ryodmpOS-LnNNfMoRqMFxQPHQpQ4q8nrt0a2dVSxrDzeEA41eu0YkvFFAyJqomB54EkZkOOkFf0UIQ">michael@psyencebiomed.com</a>Forward Looking StatementsThis communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.Forward-looking statements in this communication include statements regarding the advancement of the Company's clinical development pipeline, the commencement of the anticipated study, and international interest in longevity science. These forward-looking statements are based on a number of assumptions, including the assumption that ongoing and future study results will be positive, definitive agreements governing the anticipated study will be successfully negotiated, finalized, and executed, the Company will obtain all such regulatory approvals as may be required to execute the anticipated study, that interest in longevity science will continue to grow and that the demand for psychedelic-containing products and related therapy will continue to increase. The Company cannot guarantee that the aforementioned agreements will be completed on the expected timeline or at all. Furthermore, there can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.These risks and uncertainties include, among others: (i) delays in the execution of the Company's drug development and clinical trial pipeline; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025&nbsp; and other documents filed by Psyence BioMed from time to time with the SEC.These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

First publicly listed company to actively investigate psilocybin’s potential impact on longevity

NEW YORK, November 20, 2025 – Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced &nbsp;it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs. This is a significant achievement for the Company as it prepares for the clinical development of ibogaine for substance use disorders and validates its investment in PsyLabs.This collaboration with PsyLabs is an important step in securing a long-term supply of high-quality active pharmaceutical ingredients. PsyLabs’ ibogaine is fully GMP-compliant, ensuring it meets the rigorous standards required for clinical development. The first 50 kg has already been received and is now being processed into ibogaine HCL – the purified, pharmaceutical-grade form of ibogaine designed for precise dosing in clinical research – and into Total Alkaloid Extracts, which preserve the broader spectrum of iboga alkaloids found in the natural plant. Together, these products will be supplied to the legal research and treatment industries, supporting both standardized clinical trials and research into full-spectrum therapeutic approaches.Investing in a sustainable approach ensures that ibogaine and related alkaloids derived from Tabernanthe iboga and Voacanga africana are ethically sourced and pharmaceutical grade. By prioritizing quality, sustainability, and respect for the cultural traditions connected to these plants – including fair benefit-sharing with source communities – the Company is building a vertically integrated supply chain that meets the highest standards while supporting the long-term viability of this essential resource.“A reliable, ethically sourced supply of ibogaine is critical to our development pipeline,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “This achievement not only strengthens our ability to advance our ibogaine-based clinical programs but also positions Psyence BioMed as a global leader in the emerging ibogaine sector. As international interest in ibogaine continues to accelerate, securing a sustainable and culturally respectful supply chain gives us a meaningful competitive advantage and reinforces our commitment to scientific rigor, responsible innovation, and the preservation of traditional knowledge.”“From soil to science, we will continue to ensure our ibogaine is not only the purest on the market, but the most ethically sourced,” said Tony Budden, CEO of PsyLabs. “We’re building a new standard for what ethical psychedelic production can look like – where traditional knowledge holders are partners, not just suppliers.”Today’s announcement advances Psyence BioMed – together with PsyLabs – toward a leading role in shaping the future of ibogaine development for substance use disorders and other urgent mental health needs.Learn more at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.psyencebiomed.com/">www.psyencebiomed.com</a> and on <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/psyence-biomed-ltd/">LinkedIn.</a>About Psyence BioMedPsyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The name ‘Psyence’ merges ‘psychedelics’ and ‘science,’ reflecting the company’s commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.About PsyLabsPsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://psylabs.life/">www.psylabs.life</a>Contact Information for Psyence Biomedical Ltd.Email: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:ir@psyencebiomed.com">ir@psyencebiomed.com</a>Media Inquiries: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@psyencebiomed.com">media@psyencebiomed.com</a>General Information: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:info@psyencebiomed.com">info@psyencebiomed.com</a>Phone: +1 416-477-1708Investor Contact:Michael KyddInvestor Relations Advisor<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:michael@psyencebiomed.com">michael@psyencebiomed.com</a>Forward Looking StatementsThis communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.Forward-looking statements in this communication include statements regarding the advancement of the clinical development pipeline of ibogaine and the quality of the ibogaine derived or containing products under development. These forward-looking statements are based on a number of assumptions, including the assumption that all parties involved in the ibogaine supply chain will retain such valid permits and licenses as may be required to carry out their activities and that the demand for psychedelic-containing products and related therapy will continue to increase. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.These risks and uncertainties include, among others: (i) delays in the execution of the Company’s drug development and clinical trial pipeline; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025&nbsp; and other documents filed by Psyence BioMed from time to time with the SEC.These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Psyence BioMed (PBM) secured a sustainable, GMP-compliant supply of iboga bark via PsyLabs to advance its ibogaine clinical development for substance use disorders.

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that, through its strategic investment in PsyLabs, it is now the only publicly listed psychedelics company with active operations and manufacturing capabilities based in Africa – the natural and original source of ibogaine.Derived from the Tabernanthe iboga shrub native to Central and West Africa, ibogaine has been used for generations in traditional healing and spiritual practices. Establishing a presence directly at the source strengthens traceable, sustainable, and responsible access to this rare compound. It also places Psyence BioMed in a uniquely advantageous position within the psychedelics sector, with direct access to ibogaine at its origin and the ability to control quality from source to finished product.PsyLabs operates from a GMP-compliant facility in Southern Africa, where it produces highly purified, EU GMP-grade psychedelic compounds from natural sources, including psilocybin and ibogaine. The Company’s vertical integration across cultivation, extraction, and purification strengthens security of supply and rapid scalability.Jody Aufrichtig, Chief Executive Officer of Psyence BioMed, stated:“Our investment in PsyLabs strengthens a world-class supply chain and positions us at the forefront of nature-derived psychedelic drug development. This is not just about sourcing compounds – it’s about building a sustainable, ethical, and science-driven platform that can deliver breakthrough therapies to patients globally.”Tony Budden, CEO of PsyLabs, added:“This unique footprint in Africa offers more than operational efficiency – it’s a strategic differentiator. Africa holds deep traditional knowledge and access to rare, valuable plant medicines. We’ve built our model around ethical sourcing and honoring this wisdom through science.”Psyence BioMed shareholders benefit from this presence, gaining early access to pipeline products, IP development, and supply channels as the global demand for psychedelic APIs accelerates.A Global Surge in Ibogaine InnovationMomentum surrounding ibogaine as a potential treatment for addiction and mental health disorders continues to accelerate worldwide. Recent observational research (<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=parpNCK3aMgMPAUyivXIbFPto0YeXtRl_53eIR-W6v2ToQtPvg5FNZpmJw64ZK3d9T8uphjwOKhodzMqBOGPwlBBV7FeONT0-wAgyqaqJCEwzu9TI7cIJNqKmskNyA3c">source</a>) has shown promising results for ibogaine in treating substance use and mood disorders, sparking growing interest in its potential for PTSD in veterans. In one 2024 study of 30 Special Operations Forces veterans with traumatic brain injuries – 77% of whom met PTSD criteria – participants who underwent ibogaine-assisted therapy in Mexico experienced immediate and significant reductions in PTSD symptoms, functional impairment, and suicidal ideation.Building on this growing body of evidence, in 2025, the State of Texas allocated $50 million to fund clinical research on ibogaine, establishing a consortium of universities, hospitals, and drug developers with the goal of developing a U.S. FDA-approved treatment for opioid use disorder and related conditions. The initiative, championed by former Governor Rick Perry, aims to position Texas as a leading center for psychedelic medicine research.At the same time, global pharmaceutical interest in ibogaine and its analogs is intensifying. In August 2025, AbbVie acquired Gilgamesh Pharmaceuticals’ investigational compound Bretisilocin, a novel therapy for major depressive disorder, and established Gilgamesh Pharma Inc. to continue developing its pipeline, including a cardio-safe ibogaine analog designed to retain ibogaine’s therapeutic benefits while reducing cardiac risk (<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=parpNCK3aMgMPAUyivXIbF7YyteJrT7CV2EXVGdVKZEzMaaN_gutwyCcbZX3tpFH1Qijq1dX8nHmlTjTJfWyWGW3YHEb-rkJ-ytbNLAp_l8gF0O0a5cGtRKNwBVQThp0WMgkW4oOZWwKh26BbTvIHHcc_um7j4wauOn5FAdo7QXzxWETdn4n-7fH8b1DF3GtAurpYrs6AEFfAgkgAHJlItZf-XKkNA-L3Qy4Okuq3962fzqmUnX7HJdkMR7rqimiasb_22XUj6T8lf9FcUWa0dVC4-PTwOVH5n-tBJ-noRs=">source</a>). The acquisition highlights the growing recognition of ibogaine’s clinical potential and advances the development of next-generation analogs – an area in which Psyence BioMed is already actively engaged through its operations, partnerships, and ongoing research.“When state governments like Texas are investing $50 million in ibogaine research and leading pharmaceutical companies like AbbVie are acquiring psychedelic-inspired assets, it validates what Psyence BioMed is building. By operating at the natural source in Africa, we are uniquely positioned to supply, study, and advance ibogaine as it transitions from traditional use to mainstream medicine,” added Aufrichtig.Psyence BioMed’s vertically integrated model offers secure, compliant, and ethical access to naturally derived ibogaine for research and development. As ibogaine moves into clinical and commercial phases, Psyence BioMed’s position at the intersection of science, sustainability, and supply chain control provides a critical foundation for the next generation of psychedelic medicine.About PsyLabsPsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.www.psylabs.lifeAbout Psyence BioMedPsyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The name ‘Psyence’ merges ‘psychedelics’ and ‘science,’ reflecting the company’s commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.Learn more at www.psyencebiomed.com and on LinkedIn.Contact Information for Psyence Biomedical Ltd. Email: ir@psyencebiomed.com&nbsp; Media Inquiries: media@psyencebiomed.com General Information: info@psyencebiomed.com Phone: +1 416-477-1708Investor Contact: Michael Kydd Investor Relations Advisor michael@psyencebiomed.comForward Looking StatementsThis communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.Forward-looking statements in this communication include statements regarding the anticipated benefits to be derived by shareholders from a presence in Africa and the speed of the anticipated increase in demand for psychedelic APIs. These forward-looking statements are based on a number of assumptions, including the assumption that all parties involved in the ibogaine supply chain will retain such valid permits and licenses as may be required to carry out their activities and that the demand for psychedelic-containing products and related therapy will continue to increase. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.These risks and uncertainties include, among others: (i) delays in the execution of the Company's drug development and clinical trial pipeline; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-289285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Psyence BioMed is now the only publicly listed psychedelics company with African operations and manufacturing for nature-derived psilocybin and ibogaine.

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a major clinical milestone with multiple patients successfully dosed in its ongoing Phase IIb clinical trial evaluating nature-derived psilocybin, in combination with psychotherapy, as a potential treatment for Adjustment Disorder in palliative care.This achievement demonstrates significant clinical advancement and reinforces Psyence BioMed’s position as a global leader in late-stage psychedelic drug development. Following successful patient dosing across multiple trial sites, the Company is advancing the only active Australian clinical program using a natural psilocybin formulation to treat Adjustment Disorder in palliative care – one of the most rigorous studies of its kind globally.The Phase IIb study has been strategically designed to meet regulatory expectations for pivotal clinical evidence. Its larger sample size, rigorous randomization, and multi-site structure enhance statistical power, data reliability, and the generalizability of findings.Patients have now been dosed across two active clinical sites – the Empax Center in Perth and the Mind Medicine Australia Clinic in Melbourne – reflecting strong operational readiness, recruitment efficiency, and protocol execution. The Company has also activated Paratus Clinical Research in Melbourne to expand the study to three actively enrolling sites and accelerate data collection toward topline results anticipated by year-end 2026.“The randomization and dosing of these patients across multiple independent trial sites marks an exciting and validating milestone for Psyence BioMed,” said Dr. Clive Ward-Able, Medical Director of Psyence BioMed. “With multiple sites now operational and patients progressing through screening, we are seeing strong interest and momentum. This level of engagement reinforces the importance of our work in developing psilocybin-based therapies for palliative care.”The multi-site, double-blind, placebo-controlled study is designed to enroll 87 patients across Australia. Participants receive one of two therapeutic doses of psilocybin (10 mg or 25 mg) or a low-dose comparator (1 mg), each administered alongside structured psychotherapy. The study will assess efficacy, safety, and durability of response, with the goal of advancing psilocybin as a potential first-in-class treatment for Adjustment Disorder in palliative care settings.“This pivotal moment reflects the extraordinary effort and precision required to achieve multiple patient dosing across independent clinical sites,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “It demonstrates not only our team’s operational excellence but also the maturity of our clinical infrastructure. With a trial design that meets rigorous regulatory standards, Psyence BioMed is generating high-quality data to support future approvals, commercial readiness, and the advancement of a nature-derived psilocybin therapy for patients facing adjustment disorder in palliative care.”About Psyence BioMedPsyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The company is committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.Learn more at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=GJ8pzeEUaInOE8JXAQHTJ0Smwm5ro2Ut1o2fllUBGUNF55WLsZiVtdIpwERbrzgRnkMRK05dIHpr7nMtBhJDg2ilJ3qXZK0vfJ7BKZkVfk4=">www.psyencebiomed.com</a> and on <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=W_QiWAp7vAMOlXdap48QHBxEV9z0DUOLHG-zG3oW00YH4DRBjx_bNEbxf7YUKkVWLxvYfwTLyHE4M4qe55f46u3zPo3Ko-UJaHWjOldJWVYAlco3lgmGwikYdDIRmmgW">LinkedIn.</a>Contact Information for Psyence Biomedical Ltd. Email: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=i5YA-7fmi3ch7qqY9038SXOdjbrzPDbxbwyH4MqwyL3bvHyGkvLW1pfojT9ufClU6Pec-mBU4TNsF2rPeoa6PisGI186cNfARecoJSh_vMQ=">ir@psyencebiomed.com</a>&nbsp;&nbsp;&nbsp; Media Inquiries: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=vSH0_WHIv4yJ-bTOinwBqnZwXG1m8dev27RLQ6MeKJwrcu0TxnNpFSAGeL9xrjE5yOcZ4T7cZm9_oKp5r-i6ghWG1KcXYwxBQ24gBKrWkxHxMiv_59_Vt3UISyA9ouPd">media@psyencebiomed.com</a> General Information: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=G6uCHKkkDUkeH5h72b3NZjP8vnBh6gkgI9lfyiIGWV8fAKwfSpVQZbaIf4sxvGOmh61L8Owu94TV9nELX57JcVgBjIQ26Spr6UdrYd7OkRU=">info@psyencebiomed.com</a> Phone: +1 416-477-1708Investor Contact: Michael Kydd Investor Relations Advisor <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=xmufE7WibFL8VdTA0EL0wzMXr8Rr7nVaIdcq8samjEWn5xAp4holcrpQ8WTrlvBy3QUK3d4oOHQc4HLgRj2kNxeG8NKfMzDnBC8AVCoow2TAlADxkR_zPR1_Y78HhRgX">michael@psyencebiomed.com</a>Forward Looking StatementsThis communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial, trial execution and patient enrollment and generation of trial results. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule, topline data from this trial will be positive, and that the demand for psychedelic-assisted therapy will continue to increase. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-289285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Mind Medicine Australia clinic joins Psyence BioMed’s expanding network of clinical sites as enrollment accelerates in the landmark Phase IIb study for Adjustment Disorder in palliative care

NEW YORK, November 3, 2025 – Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet mental health needs, today announced it has made a USD$3,500,000 follow-on investment in PsyLabs, a leading producer of purified psychedelic active pharmaceutical ingredients (APIs).This investment solidifies PsyLabs’ position as a primary supplier of high-quality, GMP-grade psychedelic compounds, including psilocybin and ibogaine, for Psyence BioMed’s clinical research programs. The enhanced collaboration ensures Psyence BioMed continues to have access to an ethical, sustainable, and reliable supply of premium psychedelic compounds to advance its clinical pipeline. This investment made on August 15th, 2025, follows-on from the previously made USD$500,000 investment in PsyLabs in April 2025.“We are committed to advancing nature-derived psychedelics and building a responsible, global supply chain,” said Psyence BioMed Chief Executive Officer, Jody Aufrichtig. “This new investment is a deliberate step toward building a fully integrated company – from cultivation to clinical development. This strategic approach not only secures access to the highest quality compounds for our trials but also creates long-term value for our investors by ensuring sustainability, scalability, and competitive differentiation in a rapidly evolving market,” added Aufrichtig.PsyLabs’ state-of-the-art facility in Southern Africa utilizes the region’s rich botanical heritage to produce psychedelic compounds under strict ethical and sustainable practices. Psyence BioMed is the first publicly listed company with a dedicated investment in Southern African psychedelic production, underscoring the Company’s commitment to accessing regional expertise while advancing global psychedelic research.“This continued investment from Psyence BioMed is a testament to the strength of our partnership and the quality of our products,” said Tony Budden, CEO of PsyLabs. “We are proud to support Psyence BioMed’s pioneering clinical work with our premium, sustainably produced compounds.”With this expanded partnership, Psyence BioMed strengthens its leadership position in the emerging psychedelic therapeutics sector, advancing both near-term clinical development and long-term commercial opportunities.Certain executives, including the Chief Executive Officer, the Chief Financial Officer and the General Counsel, and an independent director, of Psyence BioMed, provide consulting services to PsyLabs in exchange for consulting fees. Such individuals own less than 5% of the outstanding shares of PsyLabs in the aggregate. Certain of these individuals are also members of the board of directors of a wholly owned subsidiary of PsyLabs.About Psyence BioMedPsyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The name ‘Psyence’ merges ‘psychedelics’ and ‘science,’ reflecting the company’s commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.Learn more at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.psyencebiomed.com/">www.psyencebiomed.com</a> and on <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/psyence-biomed-ltd/">LinkedIn.</a>About PsyLabsPsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.psylabs.life/">www.psylabs.life</a>Contact Information for Psyence Biomedical Ltd.Email: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:ir@psyencebiomed.com">ir@psyencebiomed.com</a>Media Inquiries: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@psyencebiomed.com">media@psyencebiomed.com</a>General Information: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:info@psyencebiomed.com">info@psyencebiomed.com</a>Phone: +1 416-477-1708Investor Contact:Michael KyddInvestor Relations Advisor<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:michael@psyencebiomed.com">michael@psyencebiomed.com</a>Forward Looking StatementsThis communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.Forward-looking statements in this communication include statements regarding the advancement of the Company’s clinical pipeline and the creation of long-term shareholder value. These forward-looking statements are based on a number of assumptions, including the assumption that all parties involved in the ibogaine supply chain will retain such valid permits and licenses as may be required to carry out their activities and that the demand for psychedelic-containing products and related therapy will continue to increase. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.These risks and uncertainties include, among others: (i) delays in the execution of the Company’s drug development and clinical trial pipeline; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Psyence BioMed made a $3.5 million follow-on investment in PsyLabs to secure a primary supply of high-quality psychedelic compounds for its clinical research programs.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

Equity

This account has been verified as an official PBM representative.

Verified Account

Psyence BioMed

Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company was founded on February 25, 2021 and is headquartered in Toronto, Canada.

Current Price	$0.67
Prev Close	$0.6701
Open	$0.6882
Dividend Yield	0.00%
50-Day Moving Average	$1.53
Beta	1.92
Avg. Volume	2.62M
PE Ratio	-0.04

52-Week High	$17.37
52-Week Low	$0.6147
Market Capitalization	$1.25M
EPS (Annual)	$1.78
Price to Book	0.11
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PBM
Psyence Biomedical Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest PBM News

PBMPsyence Biomedical Ltd.